Anthropic has unveiled Claude Science, its latest flagship product aimed at revolutionizing the workflow for researchers, particularly in the pharmaceutical industry. This AI-driven workbench seeks to automate and unify scientific research processes, making it an invaluable tool for scientists. By launching Claude Science, Anthropic aims to enhance its revenue streams ahead of an anticipated IPO, positioning itself alongside major tech players in healthcare. The platform is designed to streamline research tasks and includes applications such as pre-clinical drug trials, with a focus on drug discovery. Anthropic plans to leverage Claude Science as a catalyst for innovation in AI research, although the sector has seen limited FDA approvals for AI-generated drugs so far.